Comparative Pharmacology
Head-to-head clinical analysis: BLEOMYCIN SULFATE versus JELMYTO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BLEOMYCIN SULFATE versus JELMYTO.
BLEOMYCIN SULFATE vs JELMYTO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bleomycin acts by chelating metal ions (primarily iron) and producing reactive oxygen species that cause single- and double-strand DNA breaks, leading to inhibition of DNA, RNA, and protein synthesis.
JELMYTO (mitomycin) is a mitomycin-containing gel that induces apoptosis by cross-linking DNA, inhibiting DNA synthesis, and producing reactive oxygen species, with additional local tumoricidal effects via thermal ablation of the mitomycin-containing hydrogel.
10-20 units/m2 IV, IM, or SC once weekly or twice weekly; cumulative lifetime dose should not exceed 400 units. For Hodgkin lymphoma, 10 units/m2 IV on days 1 and 15 of a 28-day cycle.
Instill 4 mg (1 vial) into the renal pelvis via ureteral catheter or nephrostomy tube, once weekly for 6 weeks, followed by monthly maintenance for up to 11 months. Administer 2 mL of sterile water for irrigation through the catheter to ensure delivery; clamp for 1 hour.
None Documented
None Documented
2-4 hours; prolonged in renal impairment up to 20+ hours.
Following intravesical administration, systemic absorption is negligible, so terminal half-life is not clinically relevant. Mitomycin given intravenously has a terminal half-life of 23-78 minutes (triphasic); this is not applicable for intravesical JELMYTO.
Renal: 60-70% unchanged; impaired renal function necessitates dose adjustment.
JELMYTO (mitomycin) is not absorbed systemically after intravesical administration; urinary excretion is the primary route of elimination of the administered dose. Less than 1% of the dose is absorbed and undergoes hepatic metabolism and biliary/fecal excretion.
Category C
Category C
Antineoplastic Antibiotic
Antineoplastic Antibiotic